Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 55 % of short-term debt in 2025; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 3.7 to 2.8.
Financials
Financial year 2025
NIVELPHARMA from Nivelles, company number BE0479701721, closed financial year 2025 with a result of € 65,451 after tax. For that financial year NIVELPHARMA recorded a gross margin of € 278,623 and equity of € 64,316. Compared with financial year 2024, the result moved from € 33,080 to € 65,451. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 64,316
▼ 48% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 65,451
▲ 98% vs 2024
Profit after tax over the fiscal year.
€ 106,327
▼ 19% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 125,500 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
2.8
▼ 0.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 139,064
▼ 29% vs 2024
€ 49,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 20,062
▼ 30% vs 2024
€ 9,061 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 48,047
▼ 22% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 23,433
▲ 21% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 304,381 | € 274,115 | € 274,265 | € 278,623 | ▲ 2% |
| Profit after taxes | € 29,480 | € 6,283 | € 33,080 | € 65,451 | ▲ 98% |
| Equity | € 85,002 | € 91,286 | € 124,365 | € 64,316 | ▼ 48% |
| Total debts | € 425,102 | € 387,865 | € 352,473 | € 375,853 | ▲ 7% |
| Cash | € 110,771 | € 80,605 | € 131,231 | € 106,327 | ▼ 19% |
| Land & buildings | € 89,575 | € 76,957 | € 64,339 | € 51,721 | ▼ 20% |
| Retained profit | € 45,002 | € 51,286 | € 84,365 | € 24,316 | ▼ 71% |
| Dividend | € 0 | € 0 | € 0 | € 125,500 | |
| Bank debt | € 22,290 | € 45,547 | € 28,796 | € 20,062 | ▼ 30% |
| Balance sheet total | € 510,104 | € 479,151 | € 476,839 | € 440,169 | ▼ 8% |
| Employees (FTE) | 4.3 | 3.7 | 3.3 | 2.8 | ▼ 0.5 |
By gross margin, NIVELPHARMA ranks 5th of 10 companies with main activity “Detailhandel in farmaceutische producten” in Nivelles that publish figures (fiscal year 2025).
Key figures of NIVELPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about NIVELPHARMA the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to NIVELPHARMA?
What happened at NIVELPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 65,451 (▲ 98% vs 2024). filed late Source: NBB ↗
- JOELLE DE RUYVER became a director. NBB
- New establishment in Nivelles. KBO
- Start of the company according to the CBE. KBO
In short
From € 29,480 profit in 2022 to € 65,451 profit in 2025.
Paid € 52,316 in corporate taxes since 2022.
Best year ever: 2025, with € 65,451 profit.
On average € 99,500 of value added per employee in 2025.
Management
Behind NIVELPHARMA is JOELLE DE RUYVER.
Directors
According to the 2025 annual accounts
JOELLE DE RUYVER
Manager
since 2013
Establishments
Establishment units
Physical locations of this company
Chaussée de Mons 47
1400 Nivelles
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Nivelles
Same main activity (Detailhandel in farmaceutische producten), 11 active companies in Nivelles, largest first.
€ 24 million revenue · 2025
€ 831,424 gross margin · 2025
€ 415,999 gross margin · 2025
€ 406,486 gross margin · 2025
€ 332,643 gross margin · 2025
€ 213,185 gross margin · 2025
Details
- Company number
- 0479.701.721
- VAT number
- BE 0479.701.721
- Registered office
- Chaussée de Mons 47, 1400 Nivelles
- Names & denominations
- NIVELPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 5 March 2003
- Peppol
- Active · Active since 8 May 2024
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers